IM-862 in Treating Patients With Recurrent Ovarian Cancer
Status:
Completed
Trial end date:
2001-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: IM-862 may stop the growth of ovarian cancer by stopping blood flow to the tumor.
PURPOSE: Phase I trial to study the effectiveness of IM-862 in treating patients who have
recurrent ovarian cancer after treatment with chemotherapy and surgery.